Irinotecan
- Generic Name
- Irinotecan
- Brand Names
- Camptosar, Onivyde, Onivyde pegylated liposomal (previously known as Onivyde)
- Drug Type
- Small Molecule
- Chemical Formula
- C33H38N4O6
- CAS Number
- 97682-44-5
- Unique Ingredient Identifier
- 7673326042
- Background
Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cell death. It is a derivative of camptothecin. Irinotecan was approved for the treatment of advanced pancreatic cancer in October, 2015 (irinotecan liposome injection, trade name Onivyde).
- Indication
For the treatment of metastatic colorectal cancer (first-line therapy when administered with 5-fluorouracil and leucovorin). Also used in combination with cisplatin for the treatment of extensive small cell lung cancer. Irinotecan is currently under investigation for the treatment of metastatic or recurrent cervical cancer. Also used in combination with fluorouracil and leucovorin for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy.
- Associated Conditions
- Esophageal Cancer, Ewing's Sarcoma, Gastric Cancer, High Grade Glioma: Glioblastoma (GBM), Metastatic Cervical Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Cancer, Rhabdomyosarcomas, Small Cell Lung Cancer (SCLC), Stage IV Colorectal Cancer, Recurrent, metastatic Colorectal carcinoma, Refractory, metastatic Pancreatic adenocarcinoma
- Associated Therapies
- -
Irinotecan and Capecitabine in Treating Women With Advanced Breast Cancer
- Conditions
- First Posted Date
- 2004-05-17
- Last Posted Date
- 2011-03-09
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 12
- Registration Number
- NCT00083148
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
Irinotecan With Docetaxel in Treating Patients With Recurrent or Metastatic Non-small Cell Lung Cancer
- First Posted Date
- 2004-05-03
- Last Posted Date
- 2016-07-06
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 48
- Registration Number
- NCT00003900
- Locations
- 🇺🇸
Siouxland Hematology-Oncology, Sioux City, Iowa, United States
🇺🇸CCOP - Metro-Minnesota, Saint Louis Park, Minnesota, United States
🇨🇦Saskatchewan Cancer Agency, Regina, Saskatchewan, Canada
Irinotecan in Treating Patients With Advanced Gallbladder or Bile Duct Cancer
- First Posted Date
- 2004-04-30
- Last Posted Date
- 2016-07-06
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 40
- Registration Number
- NCT00003276
- Locations
- 🇺🇸
CCOP - Scottsdale Oncology Program, Scottsdale, Arizona, United States
🇺🇸CCOP - Illinois Oncology Research Association, Peoria, Illinois, United States
🇺🇸CCOP - Cedar Rapids Oncology Project, Cedar Rapids, Iowa, United States
Irinotecan and Paclitaxel in Treating Patients With Metastatic or Recurrent Cancer
- Conditions
- Interventions
- First Posted Date
- 2004-04-29
- Last Posted Date
- 2013-09-05
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 21
- Registration Number
- NCT00002939
- Locations
- 🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States
Docetaxel and Irinotecan in Treating Patients With Advanced Solid Tumors
- Conditions
- First Posted Date
- 2004-04-28
- Last Posted Date
- 2009-08-25
- Lead Sponsor
- Yale University
- Target Recruit Count
- 47
- Registration Number
- NCT00004923
- Locations
- 🇺🇸
Yale Comprehensive Cancer Center, New Haven, Connecticut, United States
🇺🇸Bennett Cancer Center, Stamford, Connecticut, United States
Combination Chemotherapy in Treating Patients With Stage III Colon Cancer
- First Posted Date
- 2004-04-27
- Last Posted Date
- 2013-10-08
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 1260
- Registration Number
- NCT00003835
- Locations
- 🇺🇸
Cancer and Leukemia Group B, Chicago, Illinois, United States
Oxaliplatin Plus Irinotecan in Treating Patients With Metastatic Gastrointestinal Cancer
- First Posted Date
- 2004-04-27
- Last Posted Date
- 2013-06-26
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 36
- Registration Number
- NCT00003427
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Irinotecan in Treating Patients With Metastatic Colorectal Cancer
- Conditions
- First Posted Date
- 2004-04-27
- Last Posted Date
- 2013-06-26
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00003544
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Irinotecan and Cyclosporine in Treating Patients With Metastatic, Advanced or Locally Recurrent Colorectal Cancer
- First Posted Date
- 2004-04-27
- Last Posted Date
- 2014-03-07
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 16
- Registration Number
- NCT00003950
- Locations
- 🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States
🇺🇸Louis A. Weiss Memorial Hospital, Chicago, Illinois, United States
🇺🇸University of Illinois at Chicago, Chicago, Illinois, United States
Olimersen and Irinotecan in Treating Patients With Metastatic or Recurrent Colorectal Cancer
- Conditions
- Locations
- 🇺🇸
Ireland Cancer Center, Cleveland, Ohio, United States
🇺🇸Brooke Army Medical Center, Fort Sam Houston, Texas, United States
🇺🇸San Antonio Cancer Institute, San Antonio, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.